Unidentified Bacterial Strain Discovered Inside China's Space Station
The microbes could potentially pose a threat to the health of astronauts on board Tiangong.
In October 2022, China launched the final module of its orbiting space station. Since then, it hasn't just been astronauts aboard Tiangong—an unusual and previously unknown microbe has also been occupying low Earth orbit.
A group of scientists examined swabs collected from inside the Tiangong space station, revealing a form of bacteria not known to inhabit Earth. The discovery, published in the International Journal of Systematic and Evolutionary Microbiology, highlights the need to study the newly identified microbial strain to protect the health of the astronauts on board the Chinese space station.
The previously unknown microbe, named Niallia tiangongensis after the space station where it was discovered, has proven especially resilient, surviving in the harsh conditions of microgravity. Tiangong's Shenzhou-15 astronauts swabbed a cabin on the space station in May 2023 as part of a survey by the China Space Station Habitation Area Microbiome Program. Follow-up studies of the swabs traced the newly discovered microbe to a strain that appears similar to Niallia circulans—a rod-shaped, spore-forming bacterium originally isolated from soil.
It's not clear whether the strain evolved on the space station or had already evolved on Earth before hitching a ride to low Earth orbit.
The newly described species can break down gelatin for nitrogen and carbon, helping it endure harsh conditions by forming a protective biofilm. It also packs its essential chemistry into tough spores, allowing it to survive in extreme environments.
Last year, scientists uncovered a mutated strain of drug-resistant bacteria thriving under the harsh conditions of space aboard the International Space Station (ISS).
Although Niallia tiangongensis and its ISS counterpart are both space-faring strains, they differ in composition and function, according to the paper.
It's not clear if the bacterium poses a threat to the Tiangong astronauts, but the scientists behind the discovery say further examination of the new strain needs to be carried out. 'Understanding the characteristics of microbes during long-term space missions is essential for safeguarding the health of astronauts and maintaining the functionality of spacecraft,' the paper reads.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 hours ago
- Associated Press
The Hong Kong Science Fair Now Open for Free Admission Registration
Over 3,000 Participating Primary and Secondary Students and Teachers Showcase 120 Shortlisted Outstanding Innovative Projects Utilising Technology with a Growing Trend Towards AI HONG KONG SAR - Media OutReach Newswire - 5 June 2025 - The Fourth Hong Kong Science Fair ('Science Fair'), organised by the Hong Kong Innovation Foundation ('HKIF'), supported by the Innovation, Technology and Industry Bureau of the HKSAR Government, and with Sino Group and the Hong Kong Council for Testing and Certification (HKCTC) as strategic partners, will take place from 28 to 29 June at the Hong Kong Convention and Exhibition Centre. Under the theme 'Think Big Be Innovative', 120 shortlisted teams from primary and secondary schools across Hong Kong will present their innovative projects at the Science Fair. These projects have incorporated various technologies, including artificial intelligence (AI), and will compete for a variety of awards. The Science Fair will also feature five interactive zones with exciting STEAM-related activities. Participants can turn corn pulp into refined snacks, operate remote-controlled cars made from upcycled household appliances, and build and race their own wooden mini cars — each activity is designed for parents and children to experience the fun of technology together! Online registration is now open for free admission, inviting the public to experience creativity in action as our younger generation presents their innovation and technology (I&T) vision for the future. Photo 1) The Fourth Hong Kong Science Fair will take place from 28 to 29 June at the Hong Kong Convention and Exhibition Centre. Online registration is now open for free admission. HKIF is committed to fostering an innovative spirit from an early age. Since its launch in 2021, the annual Science Fair has garnered widespread support from the government, tertiary institutions, scientific research organisations, and partners across various sectors, providing a vital platform to inspire the creative potential of young people. To broaden their international perspective, gold award-winning teams from the Primary, Junior Secondary, and Senior Secondary Divisions will have the opportunity to participate in the prestigious International Exhibition of Inventions Geneva in Switzerland. This year, the Science Fair has seen record levels of participation, with about 600 entries submitted by 300 local and international schools, engaging over 3,000 teachers and students. Photo 2) 120 shortlisted teams will showcase their innovative projects at the Hong Kong Science Fair. Photo 3) The three winning teams from the previous Hong Kong Science Fair received one silver and two bronze awards at this year's prestigious International Exhibition of Inventions Geneva. This year's Science Fair is also supported by the Hong Kong Council for Testing and Certification (HKCTC) as a strategic partner. A brand-new 'Testing and Certification Special Award', sponsored by HKCTC, has been introduced to deepen students' understanding of the role and importance of testing and certification in the context of I&T. Professor Wong Wing-tak, Chairman of the Hong Kong Council for Testing and Certification, stated: 'By instilling the 'precision and accuracy' values of testing and certification into their thinking from the start, these young scientists aren't just inventing but help elevate the standards of quality and safety. There is always a mind-boggling number of innovative ways we can make a difference. I will be excited to see the many good projects and this special award recognises our talents who are poised for the future.' Mr Daryl Ng, Chairman of the Hong Kong Innovation Foundation, said, 'We are grateful for the ongoing support of the HKSAR Government and our partners in nurturing innovative talent. I am delighted to see the enthusiastic response from schools to this year's Hong Kong Science Fair. With over 3,000 teachers and students participating, it underscores the aspirations of the next generation in innovation and technology. The quality of entries this year is outstanding, showcasing how AI and various technologies can be integrated to address everyday challenges, support the underprivileged, and promote sustainable development. Creativity in practice is a vital pathway for research development. I would like to express my gratitude to the Innovation, Technology and Industry Bureau for their commitment to cultivating the talent pool in this field, and to the Hong Kong Council for Testing and Certification for incorporating testing and certification into the Science Fair. This encourages students to blend creativity with theory and practice, establishing a solid foundation for their future endeavours in innovation and technology.' The Science Fair attracts tens of thousands of visitors each year, providing an exciting glimpse into the vibrant landscape of I&T in Hong Kong through a variety of engaging games and workshops. This year, visitors can explore five captivating interactive zones. The 'Refined CORNsidue Workshop' invites children to discover the wonders of food science by transforming corn pulp into nutritious snacks. In 'Racing Homey Kart', vintage appliances are converted into remote-controlled cars, allowing participants to race them around a custom-built track in thrilling fashion. The 'Formula Derby Workshop' encourages participants to design, build and race their own wooden mini cars, tackling exciting track challenges. In 'Spin with Battery Hero', aspiring participants will construct mini electronic motors using batteries, magnets, and wires to embark on a spinning adventure, while the 'Starry Sky' zone showcases light refraction and weaving, creating a mesmerising experience that takes participants beyond the galaxy. This year's Science Fair offers an array of limited-edition items, including innovation-themed stationery, plush cushions featuring the Science Fair mascots, and trendy mobile phone accessories. Visitors can participate in an on-site stamp game, collecting all four designated stamps around the venue to earn a coupon for the 'HKSF Bazaar', adding an extra layer of engagement to their experience. HKIF will use all proceeds from the 'HKSF Bazaar', with no deductions, to support the Science Fair and local community technology initiatives, helping to nurture the next generation of innovators. Photo 4) The Hong Kong Science Fair features interactive zones that offer visitors an engaging edutainment experience. Scan the QR code to make an online reservation. Hashtag: #HongKongInnovationFoundation #HKIF #HongKongScienceFair The issuer is solely responsible for the content of this announcement. About the Hong Kong Innovation Foundation The Hong Kong Innovation Foundation (HKIF) is a non-profit organisation. It believes that innovation and technology will define our future. By nurturing young minds and accelerating innovative solutions to real-life challenges, the Foundation empowers today's innovators to transform Hong Kong into a global technology hub for tomorrow. HKIF supports innovation and technology through a holistic innovation ecosystem to build a smart and sustainable future together. We provide a variety of platforms to serve different sectors of the community and foster an innovation technology ambience in society to prepare for talent development in the technology field. Website:
CNBC
4 hours ago
- CNBC
It's not just AI — China's quickly gaining an edge over the U.S. in biotech
BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China's rapid rise in biotechnology, especially for drug and agricultural development. Out of five critical tech sectors, "China has the most immediate opportunity to overtake the United States in biotechnology," the Harvard Belfer Center for Science and International Affairs said Thursday in its release of a "Critical and Emerging Technologies Index," covering AI, biotech, semiconductors, space and quantum. While the U.S. is still the leader in all five, "the narrow U.S.-China gap [in biotech] suggests that future developments could quickly shift the global balance of power," the report said. The assessment echoes growing concerns in Washington. In fact, the U.S. National Security Commission on Emerging Biotechnology struck a more urgent tone in an April report, citing two years of research. "There will be a ChatGPT moment for biotechnology, and if China gets there first, no matter how fast we run, we will never catch up," the bipartisan Congressional commission said in the report, referring to the transformative chatbot released by U.S.-based OpenAI. "Our window to act is closing. We need a two-track strategy: make America innovate faster, and slow China down," the commission said. It recommends that the U.S. government spend at least $15 billion over the next five years to support the domestic biotech sector. China's biotech industry has evolved to the point that U.S. and European pharmaceutical giants in the last several months have spent billions to acquire China-developed drugs that could treat cancer if commercialized with regulatory approval. In March, British pharmaceutical giant AstraZeneca announced it will invest $2.5 billion in a research and development center in Beijing. The Harvard Belfer Center pointed out that China's biotech strengths stem from its "dominance in pharmaceutical production and manufacturing," in addition to having more human talent than the U.S. China also has a "more flexible regulatory regime and the ability to push things out faster," Cynthia Y. Tong, one of the Harvard report's authors, told CNBC in an interview Thursday. She noted that the U.S. tends to have a longer approval process, as well as more drawn out research and development period. And just as China is developing its biotech sector, reports from the U.S. biotech hub of Cambridge and Boston are revealing layoffs and empty labs. China has long used multi-year plans and preferential state policies to encourage the development of key technologies. Biotech is no different, gaining high-level support back in 2007. "Currently, the U.S. government has no cohesive, intentional biotechnology strategy, while China is gaining ground thanks to its aggressive and carefully coordinated state-led initiatives," the U.S. security commission said. The worry is that just as Chinese restrictions on rare earths start to hit car manufacturers, Chinese dominance in biotech could become yet another form of leverage for Beijing over the U.S. and other countries. "The likelihood there's going to be cooperation [between the] U.S. and China on anything is very low, in some ways least likely on biotech and AI" because of the congressional report, said Eric Rosenbach, director of the defense, emerging technology, and strategy program at Harvard's Belfer Center. He was chief of staff at the U.S. Department of Defense from 2015 to 2017. He expects more U.S. pressure on China. It remains to be seen what that would mean in practice for businesses — though some say the future of biotech development is inherently global. Insilico Medicine, a startup using AI to cut drug discovery costs, relies on a global team spread across China, North America and the Middle East, according to its founder and CEO Alex Zhavoronkov. On Tuesday, the company announced with a paper in Nature Medicine that it was the first to see successful clinical testing with an AI-discovered drug. While Insilico's AI work typically happens in Canada and Abu Dhabi, the chemical testing and experiments are done in China, Zhavoronkov said, adding that the head of clinical development is in Boston. He declined to comment on a commercialization timeline in light of conversations with regulators. Other data shows that China has surpassed the U.S. in the number of clinical trials conducted, seen significant patent growth and boasts the most life sciences construction activity in the world. China-based Capital O venture partner Yang Fan, who previously worked in the pharmaceutical industry, said he expects the best biotech companies of the future will navigate different countries' regulations and use resources across the globe, if not benefit from arbitrage opportunities given different requirements and cost of entry in various markets. "The Chinese market is like a big supermarket for anything that can be commoditized, AI or biotechnology," he said, adding that new startups in China have to be "really good" to stand out. As AI drives innovation costs down, Fan predicts that in biotech, "the real DeepSeek moment is probably going to happen in five years."
Associated Press
5 hours ago
- Associated Press
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ('Ocugen' or the 'Company') (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP). Pursuant to the term sheet, under the license agreement Ocugen will receive upfront license fees and near-term development milestones equaling up to $11 million. The Company will be entitled to sales milestones of $1 million for every $15 million of net sales in Korea in addition to a royalty of 25% on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen will manufacture commercial supply of OCU400 under terms of a supply agreement. There are an estimated 15,000 individuals in the Republic of Korea with RP. OCU400 provides the opportunity for our partner to help thousands of patients and become a leader in gene therapy in Korea. 'This regional licensing agreement is aligned with our business development strategy to partner with well-established companies in their respective countries and regions—leveraging their networks and know-how to treat as many RP patients as possible,' said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. 'A regional approach preserves Ocugen's rights to larger geographies to maximize total patient reach while also generating return for our shareholders.' Additional details will be available once the definitive agreement between the parties is executed, which is expected to occur within the next 60 days. Ocugen is currently advancing OCU400 through Phase 3 clinical development with a target Biologics License Application filing of mid-2026. About Ocugen, Inc. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Discover more at and follow us on X and LinkedIn. Cautionary Note on Forward-Looking Statements Thispressreleasecontainsforward-lookingstatementswithinthemeaningofThePrivateSecuritiesLitigationReformActof1995,including,butnot limited to, statements regarding the terms of the definitive license and timing of a definitive agreement or if a definitive agreement will be executed at all or the anticipated benefits to Ocugen of the definitive license agreement, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should,'or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including,butnotlimitedto, Contact: Tiffany Hamilton AVP, Head of Communications [email protected]
